1. Home
  2. BEAM vs DGII Comparison

BEAM vs DGII Comparison

Compare BEAM & DGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$23.08

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Logo Digi International Inc.

DGII

Digi International Inc.

N/A

Current Price

$54.63

Market Cap

2.9B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
DGII
Founded
2017
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.9B
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
BEAM
DGII
Price
$23.08
$54.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
5
Target Price
$49.85
★ $79.60
AVG Volume (30 Days)
★ 1.8M
420.2K
Earning Date
11-03-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.31
77.05
EPS
N/A
★ 1.00
Revenue
$24,000.00
★ $430,221,000.00
Revenue This Year
N/A
$10.77
Revenue Next Year
N/A
$8.01
P/E Ratio
★ N/A
$57.47
Revenue Growth
★ 33.33
1.46
52 Week Low
$20.23
$36.89
52 Week High
$38.26
$86.84

Technical Indicators

Market Signals
Indicator
BEAM
DGII
Relative Strength Index (RSI) 40.33 28.96
Support Level $22.65 $53.51
Resistance Level $28.19 $70.30
Average True Range (ATR) 1.92 3.72
MACD -0.33 -1.76
Stochastic Oscillator 0.07 6.18

Price Performance

Historical Comparison
BEAM
DGII

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

Share on Social Networks: